This site uses cookies, tags and tracking settings to store information that help give you the very best browsing experience. If you don't change your settings, we'll assume you're happy with this. More information Dismiss this warning

Interleukin-1 effect on glycemia in the non-obese diabetic mouse at the pre-diabetic stage

in Journal of Endocrinology
Authors:
A Amrani
Search for other papers by A Amrani in
Current site
Google Scholar
PubMed
Close
,
M Jafarian-Tehrani
Search for other papers by M Jafarian-Tehrani in
Current site
Google Scholar
PubMed
Close
,
P Mormède
Search for other papers by P Mormède in
Current site
Google Scholar
PubMed
Close
,
S Durant
Search for other papers by S Durant in
Current site
Google Scholar
PubMed
Close
,
J-M Pleau
Search for other papers by J-M Pleau in
Current site
Google Scholar
PubMed
Close
,
F Haour
Search for other papers by F Haour in
Current site
Google Scholar
PubMed
Close
,
M Dardenne
Search for other papers by M Dardenne in
Current site
Google Scholar
PubMed
Close
, and
F Homo-Delarche
Search for other papers by F Homo-Delarche in
Current site
Google Scholar
PubMed
Close
Restricted access
Rent on DeepDyve

Sign up for journal news

Abstract

Cytokines, particularly interleukin 1 (IL-1) and tumor necrosis factor, are known to induce hypoglycemia in normal rodents or different experimental models of type II diabetes. We investigated, at the pre-diabetic stage, the effect of short-term administration of murine recombinant interleukin-1α (mrIL-1α) on the levels of glucose, insulin and corticosterone in the non-obese diabetic (NOD) mouse, a spontaneous model of type I diabetes. Two-month-old, pre-diabetic NOD mice of both sexes were insensitive to mrIL-1α (12·5 and 50 μg/kg) 2 h after administration, the time at which the maximal decrease (around 50%) was observed in the C57BL/6 mouse strain. Kinetic studies however showed that mrIL-1α lowered glycemia in both sexes of NOD mice, but the effect was limited and delayed. In the NOD and C57BL/6 strains, mrIL-1α had no influence on insulin levels in females, but significantly increased them in males (P<0·0001). Castration of NOD males abrogated the stimulatory effect of mrIL-1α on insulin secretion. Corticosterone secretion was stimulated by mrIL-1α in both sexes of NOD and C57BL/6 mice, and this effect was faster and greater in NOD females than in C57BL/6 females. The incomplete hypoglycemic response to mrIL-1α in females may be attributed to the anti-insulin effect of glucocorticoids, an effect which can be demonstrated when mrIL-1α is administered to adrenalectomized animals or when mrIL-1α is administered together with the glucocorticoid antagonist RU38486. In NOD males, in contrast, glucocorticoids did not play a major role in the limited hypoglycemic response to mrIL-1α, since RU38486 and adrenalectomy were not able to unmask a hypoglycemic effect. Moreover, NOD mice of both sexes were less sensitive than C57BL/6 mice to the hypoglycemic effect of insulin (2·5 U/kg), which suggests some degree of insulin-resistance in NOD mice. With regard to the effect of IL-1 on NOD mouse glycemia, therefore, these results suggest that glucocorticoids and/or androgens, according to the animal's sex, may induce a state of insulin-resistance.

Journal of Endocrinology (1996) 148, 139–148

 

  • Collapse
  • Expand